Lead optimization of 1,4-azaindoles as antimycobacterial agents

  • J Med Chem. 2014 Jul 10;57(13):5728-37. doi: 10.1021/jm500571f.
Pravin S Shirude  1 ,  Radha K Shandil ,  M R Manjunatha ,  Claire Sadler ,  Manoranjan Panda ,  Vijender Panduga ,  Jitendar Reddy ,  Ramanatha Saralaya ,  Robert Nanduri ,  Anisha Ambady ,  Sudha Ravishankar ,  Vasan K Sambandamurthy ,  Vaishali Humnabadkar ,  Lalit K Jena ,  Rudrapatna S Suresh ,  Abhishek Srivastava ,  K R Prabhakar ,  James Whiteaker ,  Robert E McLaughlin ,  Sreevalli Sharma ,  Christopher B Cooper ,  Khisi Mdluli ,  Scott Butler ,  Pravin S Iyer ,  Shridhar Narayanan ,  Monalisa Chatterji
Affiliations
  • 1. Department of Medicinal Chemistry, iMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
PMID: 24874895 DOI: 10.1021/jm500571f
Abstract

In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB Infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

Products